TY - JOUR
T1 - Retrospective Analysis for Dose Reduction to Organs at Risk with New Personalized Breast Holder (PERSBRA) in Left Breast IMRT
AU - Chen, Chiu Ping
AU - Chen, Tung Ho
AU - Chiou, Jeng Fong
AU - Chen, Yi Ju
AU - Kuo, Chia Chun
AU - Tseng, Kuo Hsiung
AU - Chung, Meng Yun
AU - Chen, Chun You
AU - Wu, Jeng You
AU - Lu, Long Sheng
AU - Hsu, Shih Ming
N1 - Funding Information:
This work was financially supported by the TMU Research Center of Cancer Translational Medicine from the Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education in Taiwan (Grant numbers: DP2-110-21121-03-C-06-01, DP2-110-21121-03-C-06-02, DP2-110-21121-03-C-06-03, DP2-109-21121-03-C-06-01, DP2-109-21121-03-C-06-02, DP2-109-21121-03-C-06-03). This research was also partially supported by the Ministry of Science and Technology (Grant numbers: MOST-110-2320-B-038-056, MOST-110-2314-B-038-138, MOST-109-2314-B-038-122, MOST-109-2314-B-038-141, MOST-109-2635-B-038-001, MOST-109-2314-B-038-072, MOST 106-2320-B-038-03), Taipei Medical University (Grant number: TMU105-AE1-B13), and the National Health Research Institutes (Grant number: NHRI-EX109-10713EI). The funders had no role in the study design or data collection, analysis, and interpretation, or in the writing and publication of this manuscript.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/9
Y1 - 2022/9
N2 - This study evaluated dose differences in normal organs at risk, such as the lungs, heart, left anterior descending artery (LAD), right coronary artery, left ventricle, and right breast under personalized breast holder (PERSBRA), when using intensity-modulated radiation therapy (IMRT). This study evaluated the radiation protection offered by PERSBRA in left breast cancer radiation therapy. Here, we retrospectively collected data from 24 patients with left breast cancer who underwent breast-conserving surgery as well as IMRT radiotherapy. We compared the dose differences in target coverage and organs at risk with and without PERSBRA. For target coverage, tumor prescribed dose 95% coverage, conformity index, and homogeneity index were evaluated. For organs at risk, we compared the mean heart dose, mean left ventricle dose, LAD maximum and mean dose, mean left lung receiving 20 Gy, 10 Gy, and 5 Gy of left lung volume, maximum and mean coronary artery of the right, maximum of right breast, and mean dose. Good target coverage was achieved with and without PERSBRA. When PERSBRA was used with IMRT, the mean dose of the heart decreased by 42%, the maximum dose of LAD decreased by 26.4%, and the mean dose of LAD decreased by 47.0%. The mean dose of the left ventricle decreased by 54.1%, the volume (V20) of the left lung that received 20 Gy decreased by 22.8%, the volume (V10) of the left lung that received 10 Gy decreased by 19.8%, the volume (V5) of the left lung that received 5 Gy decreased by 15.7%, and the mean dose of the left lung decreased by 23.3%. Using PERSBRA with IMRT greatly decreases the dose to organs at risk (left lung, heart, left ventricle, and LAD). This study found that PERSBRA with IMRT can achieve results similar to deep inspiration breath-hold radiotherapy (DIBH) in terms of reducing the heart radiation dose and the risk of developing heart disease in patients with left breast cancer who cannot undergo DIBH.
AB - This study evaluated dose differences in normal organs at risk, such as the lungs, heart, left anterior descending artery (LAD), right coronary artery, left ventricle, and right breast under personalized breast holder (PERSBRA), when using intensity-modulated radiation therapy (IMRT). This study evaluated the radiation protection offered by PERSBRA in left breast cancer radiation therapy. Here, we retrospectively collected data from 24 patients with left breast cancer who underwent breast-conserving surgery as well as IMRT radiotherapy. We compared the dose differences in target coverage and organs at risk with and without PERSBRA. For target coverage, tumor prescribed dose 95% coverage, conformity index, and homogeneity index were evaluated. For organs at risk, we compared the mean heart dose, mean left ventricle dose, LAD maximum and mean dose, mean left lung receiving 20 Gy, 10 Gy, and 5 Gy of left lung volume, maximum and mean coronary artery of the right, maximum of right breast, and mean dose. Good target coverage was achieved with and without PERSBRA. When PERSBRA was used with IMRT, the mean dose of the heart decreased by 42%, the maximum dose of LAD decreased by 26.4%, and the mean dose of LAD decreased by 47.0%. The mean dose of the left ventricle decreased by 54.1%, the volume (V20) of the left lung that received 20 Gy decreased by 22.8%, the volume (V10) of the left lung that received 10 Gy decreased by 19.8%, the volume (V5) of the left lung that received 5 Gy decreased by 15.7%, and the mean dose of the left lung decreased by 23.3%. Using PERSBRA with IMRT greatly decreases the dose to organs at risk (left lung, heart, left ventricle, and LAD). This study found that PERSBRA with IMRT can achieve results similar to deep inspiration breath-hold radiotherapy (DIBH) in terms of reducing the heart radiation dose and the risk of developing heart disease in patients with left breast cancer who cannot undergo DIBH.
KW - breast cancer
KW - intensity-modulated radiation therapy
KW - organs at risk
KW - personalized breast holder
UR - http://www.scopus.com/inward/record.url?scp=85138620140&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138620140&partnerID=8YFLogxK
U2 - 10.3390/jpm12091368
DO - 10.3390/jpm12091368
M3 - Article
AN - SCOPUS:85138620140
SN - 2075-4426
VL - 12
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 9
M1 - 1368
ER -
